Insights

Axinn Viewpoints

What’s on Antitrust Enforcers’ Minds? Federal and State Enforcer Perspectives on Health Care Transactions

On April 13-15, Axinn partners Lisl Dunlop and Leslie Overton and counsel Carol Liu attended the Health Care Transactions Conference hosted by the American Health Law Association (AHLA). In several panels throughout the conference, health care enforcers from the Federal Trade Commission (FTC) and State Attorneys General Offices shared their perspectives on health care antitrust enforcement.

Learn More

Awards & Recognitions

Axinn Wins Firm of the Year – Americas at 2026 Global Competition Review Awards

Axinn is proud to announce that it was named GCR “Firm of the Year – Americas,” recognizing an exceptional year defined by the quality and impact of the firm’s antitrust work. This is the fourth time the firm has won this award, reflecting Axinn’s continued growth, deep bench of talent, and success guiding clients through complex, high-stakes competition matters.

Learn More

Axinn Viewpoints

Let’s Talk “About”. . . That Bird?

Much ink has been spilled over the meaning of “about” when used to characterize an amount or a range recited in a patent claim. Sometimes the patent explicitly defines “about,” sometimes “about” simply means “approximately,” sometimes the scope of “about” is clarified based on arguments made during prosecution to gain allowance, and sometimes a skilled artisan might recognize the scope of “about” based on some constellation of the foregoing and knowledge in the art.

Learn More

Axinn Viewpoints

What’s on Antitrust Enforcers’ Minds? Federal and State Enforcer Perspectives on Health Care Transactions

On April 13-15, Axinn partners Lisl Dunlop and Leslie Overton and counsel Carol Liu attended the Health Care Transactions Conference hosted by the American Health Law Association (AHLA). In several panels throughout the conference, health care enforcers from the Federal Trade Commission (FTC) and State Attorneys General Offices shared their perspectives on health care antitrust enforcement.

Learn More

Awards & Recognitions

Axinn Wins Firm of the Year – Americas at 2026 Global Competition Review Awards

Axinn is proud to announce that it was named GCR “Firm of the Year – Americas,” recognizing an exceptional year defined by the quality and impact of the firm’s antitrust work. This is the fourth time the firm has won this award, reflecting Axinn’s continued growth, deep bench of talent, and success guiding clients through complex, high-stakes competition matters.

Learn More

Axinn Viewpoints

Let’s Talk “About”. . . That Bird?

Much ink has been spilled over the meaning of “about” when used to characterize an amount or a range recited in a patent claim. Sometimes the patent explicitly defines “about,” sometimes “about” simply means “approximately,” sometimes the scope of “about” is clarified based on arguments made during prosecution to gain allowance, and sometimes a skilled artisan might recognize the scope of “about” based on some constellation of the foregoing and knowledge in the art.

Learn More

Axinn Viewpoints

What’s on Antitrust Enforcers’ Minds? Federal and State Enforcer Perspectives on Health Care Transactions

On April 13-15, Axinn partners Lisl Dunlop and Leslie Overton and counsel Carol Liu attended the Health Care Transactions Conference hosted by the American Health Law Association (AHLA). In several panels throughout the conference, health care enforcers from the Federal Trade Commission (FTC) and State Attorneys General Offices shared their perspectives on health care antitrust enforcement.

Learn More

Practices

Type

People

Most recent

Deals & Cases 20 results

April 27, 2026

Axinn Advises Thermo Fisher Scientific on $1.075 Billion Sale of its Microbiology Business to Astorg

Axinn advised Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, on its definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for approximately $1.075 billion. The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing.

Deals & Cases

Antitrust

January 7, 2026

Axinn Represents Park Place Technologies, GTCR, and Charlesbank in Park Place’s Acquisition by Service Express

Axinn is pleased to represent Park Place Technologies (“Park Place”), together with its existing sponsors GTCR and Charlesbank Capital Partners, as global coordinating antitrust counsel in Park Place’s acquisition by Service Express, a Warburg Pincus portfolio company. Park Place and Service Express have merged to create a global data center services company with more than 3,000 employees and more than 25,000 customers across North America, Europe, Asia, and South America.

Deals & Cases

October 30, 2025

Axinn Advises Boyd Group Services on its Acquisition of Joe Hudson’s Collision Center

Axinn is pleased to announce that it is serving as antitrust counsel to Boyd Group Services Inc. (“Boyd”; TSX: BYD) in its definitive agreement to acquire Joe Hudson’s Collision Center (“JHCC”) from TSG Consumer Partners LP. Valued at approximately $1.3 billion, the transaction adds 258 collision repair locations across 18 U.S. states, expanding Boyd’s footprint and establishing a leading presence in the growing U.S. Southeast region. Closing is anticipated in the fourth quarter of 2025, subject to customary conditions and regulatory requirements.

Deals & Cases

Antitrust

October 29, 2025

Axinn Advises Thermo Fisher Scientific in Strategic Acquisition of Clario Holdings Inc.

Axinn is pleased to announce that it is acting as regulatory counsel to Thermo Fisher Scientific Inc. (“Thermo Fisher”) in its recently announced definitive agreement to acquire Clario Holdings, Inc. (“Clario”), a global leader in clinical-trial endpoint data solutions, from a shareholder group led by Astorg and Nordic Capital, Novo Holdings, and Cinven. The transaction, valued at approximately $9 billion in cash at closing, plus potential additional performance-based payments, underscores Thermo Fisher’s strategy to deepen its digital, data, and artificial intelligence capabilities in clinical research and biopharma services markets. Following the close, Clario will become part of Thermo Fisher’s Laboratory Products & Biopharma Services segment.

Deals & Cases

Antitrust

September 4, 2025

Axinn Advises Thermo Fisher Scientific on its Acquisition of the Purification & Filtration Business of Solventum

Axinn is pleased to represent Thermo Fisher Scientific, the world leader in serving science, as regulatory counsel on its acquisition of the Purification & Filtration business of Solventum for approximately $4 billion in cash. This acquisition strengthens Thermo Fisher’s bioproduction offerings and will expand its reach into industries requiring ultra-pure water, including battery, semiconductor, and medical device manufacturing.

Deals & Cases

Antitrust

August 19, 2025

Axinn Advises AssuredPartners in its Acquisition by Arthur J. Gallagher & Co.

Axinn is pleased to represent leading U.S. insurance broker AssuredPartners on the antitrust aspects of its $13.45 billion acquisition by Arthur J. Gallagher & Co. The transaction, which closed on August 18, 2025, builds upon the two companies’ client-focused cultures and enhances their product offerings, customer service capabilities, and industry expertise. The transaction received a Second Request on March 6, 2025 and closed without remedy on August 18, 2025.

Deals & Cases

July 22, 2025

Axinn Serves as Global Coordinating Counsel for Worldpay in its $24.5 Billion Acquisition by Global Payments

Axinn is pleased to represent Worldpay as global coordinating antitrust counsel in its $24.5 billion acquisition by Global Payments as part of a transformative three-way transaction. The other interrelated deals include Global Payments’ divestiture of its issuer processing business, Total System Services LLC (TSYS), to Fidelity National Information Services, Inc., and the acquisition by GTCR, which owns the majority of Worldpay, of 15% of Global Payments’ outstanding shares.

Deals & Cases

Antitrust

March 19, 2025

Axinn Represents Berkshire Partners in the Antitrust Aspects of its Acquisition of Forcura and Medalogix

Axinn successfully represented Berkshire Partners in the antitrust aspects of the parallel acquisitions of two post-acute care software companies: Forcura, an intelligent workflow management company; and Medalogix, a clinical decision support company. Together, the two complementary companies create a leading healthcare technology platform that brings real efficiencies and improved patient care, starting with home-based healthcare and expanding across the broader healthcare industry. Berkshire is the majority owner of the combined company.

Deals & Cases

Antitrust

February 5, 2025

Axinn Represents Sectigo, Inc. in Securing Antitrust Clearance for Acquisition of Entrust’s Public Certificate Business

Axinn is pleased to have represented Sectigo, Inc., a global leader in digital certificates and automated Certificate Lifecycle Management, in the antitrust aspects of its acquisition of Entrust’s public certificate business. The acquisition, which marked a transformative milestone for Sectigo, doubled Sectigo’s footprint, allowing for new growth opportunities to a broader customer base. The deal closed on January 29, 2025.

Deals & Cases

Antitrust

What’s on Antitrust Enforcers’ Minds? Federal and State Enforcer Perspectives on Health Care Transactions

Axinn Wins Firm of the Year – Americas at 2026 Global Competition Review Awards

Axinn Partners John Harkrider and Craig Minerva Win 2026 Concurrences Antitrust Writing Award

Let’s Talk “About”. . . That Bird?

What’s on Antitrust Enforcers’ Minds? Federal and State Enforcer Perspectives on Health Care Transactions

Axinn Wins Firm of the Year – Americas at 2026 Global Competition Review Awards

Axinn Partners John Harkrider and Craig Minerva Win 2026 Concurrences Antitrust Writing Award

Let’s Talk “About”. . . That Bird?

What’s on Antitrust Enforcers’ Minds? Federal and State Enforcer Perspectives on Health Care Transactions

Insights

Deals & Cases 20 results

Events